{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,15]],"date-time":"2025-10-15T17:21:27Z","timestamp":1760548887852},"reference-count":68,"publisher":"Wiley","issue":"S101","license":[{"start":{"date-parts":[[2011,1,11]],"date-time":"2011-01-11T00:00:00Z","timestamp":1294704000000},"content-version":"vor","delay-in-days":10967,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["obgyn.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Acta Obstet Gynecol Scand"],"published-print":{"date-parts":[[1981,1]]},"abstract":"<jats:p>This paper reviews the theoretical background for the use of progestins in advanced breast cancer and the clinical experience obtained from 13 major studies.<\/jats:p><jats:p>The average rate of response is about 30%, with somewhat higher rates when the dominant site of disease is localized to soft tissue and to bones, compared with viscera. Furthermore it seems that cross resistance between progestin therapy and other endocrine therapies is only partial. However, response rates related to previous therapy and to important prognostic variables such as age of the patient, disease\u2010free interval and hormone receptor content of the tumor tissue are poorly elucidated. Only limited data are available concerning response rate in relation to dose and route of administration and data from prospective randomized trials to analyze these relations are still lacking.<\/jats:p><jats:p>Considering the only modest side effects of treatment with progestins and the clinical and theoretical evidence favoring a mode of action different from that of other endocrine therapies, progestins are drugs with interesting qualities. Therefore future controlled studies with progestins alone or in combination with other systemic therapies should be carried out to establish the therapeutic efficacy of progestin therapy in primary and advanced disease.<\/jats:p>","DOI":"10.3109\/00016348109157810","type":"journal-article","created":{"date-parts":[[2009,12,8]],"date-time":"2009-12-08T18:02:06Z","timestamp":1260295326000},"page":"39-46","update-policy":"http:\/\/dx.doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":22,"title":["Treatment of Advanced Breast Cancer with Progestins: A review"],"prefix":"10.1111","volume":"60","author":[{"given":"J.","family":"L\u00f8ber","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C.","family":"Rose","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Salimtschik","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"H. T.","family":"Mouridsen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2011,1,11]]},"reference":[{"key":"e_1_2_1_2_1","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(197404)33:4<907::AID-CNCR2820330403>3.0.CO;2-Y"},{"issue":"1144","key":"e_1_2_1_3_1","first-page":"702","article-title":"Letter to the Editor","volume":"191","author":"Bugalossi P.","year":"1963","journal-title":"Practitioner"},{"key":"e_1_2_1_4_1","first-page":"1151","article-title":"The anti\u2010estrogenic activity of progestins","volume":"63","author":"Bonton M. M.","year":"1979","journal-title":"Cancer Treat Rep"},{"key":"e_1_2_1_5_1","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(197706)39:6<2923::AID-CNCR2820390679>3.0.CO;2-3"},{"key":"e_1_2_1_6_1","doi-asserted-by":"publisher","DOI":"10.1210\/endo-103-5-1768"},{"key":"e_1_2_1_7_1","first-page":"13","article-title":"Pharmacokinetics and metabolism of medroxyprogesterone acetate. Influence of the route of administration and of its physical state","volume":"2","author":"Castegnaro E.","year":"1971","journal-title":"Steroidologia"},{"key":"e_1_2_1_8_1","first-page":"109","article-title":"Progress report: Results of studies by CBCG 1956\u201360","volume":"11","author":"Cooperative Breast Cancer Group","year":"1961","journal-title":"Cancer Chemother Rep"},{"key":"e_1_2_1_9_1","first-page":"1","volume":"41","author":"Cooperative Breast Cancer Group: Results of studies of CBCG 1961\u201363","year":"1964","journal-title":"Cancer Chemother Rep"},{"key":"e_1_2_1_10_1","doi-asserted-by":"publisher","DOI":"10.1210\/jcem-33-3-459"},{"key":"e_1_2_1_11_1","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1177\/030089167806400204","article-title":"High dose medroxyprogesterone acetate (MPA) treatment in metastatic carcinoma of the breast: A dose\u2010response evaluation","volume":"64","author":"Cuna G. R.","year":"1978","journal-title":"Tumori"},{"key":"e_1_2_1_12_1","volume-title":"High dose medroxyprogesterone acetate (HD\u2010MPA) combined with chemotherapy for metastatic breast carcinoma","author":"Cuna G. R."},{"key":"e_1_2_1_13_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0009-9260(63)80037-9"},{"key":"e_1_2_1_14_1","first-page":"1219","article-title":"Treatment of advanced breast cancer with high dose of MPA and bromocriptine: Correlation with steroid receptor content","volume":"63","author":"Dogliotti L.","year":"1979","journal-title":"Cancer Treat Rep Abstr"},{"key":"e_1_2_1_15_1","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(197312)32:6<1317::AID-CNCR2820320604>3.0.CO;2-A"},{"key":"e_1_2_1_16_1","unstructured":"1977 Farlutal Review. Farmitalia."},{"key":"e_1_2_1_17_1","first-page":"XIII","article-title":"Metabolism on synthetic progestational compounds","volume":"33","author":"Fotherby K.","year":"1965","journal-title":"Endocrinology"},{"key":"e_1_2_1_18_1","doi-asserted-by":"publisher","DOI":"10.1038\/bjc.1973.55"},{"key":"e_1_2_1_19_1","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(196901)23:1<109::AID-CNCR2820230112>3.0.CO;2-1"},{"key":"e_1_2_1_20_1","first-page":"79","article-title":"Factors influencing the absorption of medroxyprogesterone acetate","volume":"6","author":"Helmreich M. L.","year":"1965","journal-title":"Steroids"},{"key":"e_1_2_1_21_1","doi-asserted-by":"publisher","DOI":"10.1210\/jcem-42-5-912"},{"key":"e_1_2_1_22_1","doi-asserted-by":"publisher","DOI":"10.1038\/254337a0"},{"key":"e_1_2_1_23_1","doi-asserted-by":"publisher","DOI":"10.1210\/endo-98-2-438"},{"key":"e_1_2_1_24_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.48.3.379"},{"key":"e_1_2_1_25_1","first-page":"1163","article-title":"Two principles in endocrine therapy of cancers: Hormone deprival and hormone interference","volume":"25","author":"Huggins C.","year":"1965","journal-title":"Cancer Res"},{"key":"e_1_2_1_26_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0010-7824(76)80060-1"},{"key":"e_1_2_1_27_1","article-title":"Progestagens and advanced breast cancer","volume":"1049","author":"Jones V.","year":"1971","journal-title":"Lancet"},{"key":"e_1_2_1_28_1","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-87-6-687"},{"key":"e_1_2_1_29_1","first-page":"251","article-title":"Response to medroxyprogesterone acetate (NSC\u201026386) as secondary hormone therapy for metastatic breast cancer in postmenopausal women","volume":"60","author":"Klaassen D. J.","year":"1976","journal-title":"Cancer Treat Rep"},{"key":"e_1_2_1_30_1","doi-asserted-by":"publisher","DOI":"10.1007\/BF00258291"},{"key":"e_1_2_1_31_1","first-page":"25","volume-title":"Recent Progress in Hormone Research, vol. 34","author":"Labrie F.","year":"1978"},{"key":"e_1_2_1_32_1","first-page":"260","volume-title":"Adriamycin, Part IV","author":"Longueville J.","year":"1975"},{"key":"e_1_2_1_33_1","doi-asserted-by":"publisher","DOI":"10.1016\/0022-4731(79)90322-4"},{"key":"e_1_2_1_34_1","doi-asserted-by":"publisher","DOI":"10.1177\/030089167606200110"},{"key":"e_1_2_1_35_1","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(197902)43:2<444::AID-CNCR2820430207>3.0.CO;2-C"},{"key":"e_1_2_1_36_1","doi-asserted-by":"publisher","DOI":"10.1016\/0014-2964(73)90131-X"},{"key":"e_1_2_1_37_1","first-page":"17","volume-title":"Estrogen Receptors in Human Breast Cancer","author":"McGuire W. L.","year":"1975"},{"key":"e_1_2_1_38_1","doi-asserted-by":"publisher","DOI":"10.3109\/02841867809128249"},{"key":"e_1_2_1_39_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0305-7372(78)80017-6"},{"key":"e_1_2_1_40_1","doi-asserted-by":"publisher","DOI":"10.1210\/endo-95-6-1589"},{"key":"e_1_2_1_41_1","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-68-2-328"},{"key":"e_1_2_1_42_1","first-page":"129","article-title":"Massive\u2010dose progestational therapy in oncology (medroxyprogesterone)","volume":"18","author":"Pannuti F.","year":"1976","journal-title":"Pan Med"},{"key":"e_1_2_1_43_1","first-page":"528","article-title":"Metastatic breast cancer: Treatment of pleural effusion by intramuscular massive doses of medroxyprogesterone acetate","volume":"5","author":"Pannuti F.","year":"1977","journal-title":"IRCS J Med Sci"},{"key":"e_1_2_1_44_1","first-page":"54","article-title":"Higher doses of medroxyprogesterone acetate in the treatment of advanced breast cancer IRCS","volume":"5","author":"Pannuti F.","year":"1977","journal-title":"J Med Sci"},{"key":"e_1_2_1_45_1","first-page":"49","article-title":"Metastatic breast cancer: medroxyprogesterone acetate (MPA) in premenopause; massive doses","volume":"5","author":"Pannuti F.","year":"1977","journal-title":"IRCS J Med Sci"},{"key":"e_1_2_1_46_1","first-page":"433","article-title":"Pilot trial of the use of massive doses of medroxyprogesterone acetate (MPA) orally in oncology","volume":"5","author":"Pannuti F.","year":"1977","journal-title":"IRCS J Med Sci"},{"key":"e_1_2_1_47_1","first-page":"499","article-title":"A possible new approach to the treatment of metastatic breast cancer: Massive doses of medroxyprogesterone acetate","volume":"62","author":"Pannuti F.","year":"1978","journal-title":"Cancer Treat Rep"},{"key":"e_1_2_1_48_1","first-page":"680","article-title":"Surgical adjuvant hormone therapy in breast cancer","volume":"48","author":"Pannuti F.","year":"1978","journal-title":"Arch Geschwulstforsch"},{"key":"e_1_2_1_49_1","doi-asserted-by":"publisher","DOI":"10.1159\/000214472"},{"key":"e_1_2_1_50_1","doi-asserted-by":"publisher","DOI":"10.1016\/0014-2964(79)90097-5"},{"key":"e_1_2_1_51_1","first-page":"1219","article-title":"Hormone therapy in advanced breast cancer: comparison between high dose medroxyprogesterone acetate (MPA) and tamoxifen (TMX)","volume":"63","author":"Pannuti F.","year":"1979","journal-title":"Cancer Treat Rep Abstr"},{"key":"e_1_2_1_52_1","first-page":"93","article-title":"Hormone therapy in advanced breast cancer: High dose medroxyprogesterone acetate (MPA) vs tamoxifen (TMX). Preliminary results","volume":"1","author":"Pannuti F.","year":"1980","journal-title":"Eur J Cancer"},{"key":"e_1_2_1_53_1","doi-asserted-by":"publisher","DOI":"10.1016\/0022-4731(76)90096-0"},{"key":"e_1_2_1_54_1","first-page":"335","volume-title":"Cancer Hormone Therapy, vol. 6","author":"Pearson O. H.","year":"1959"},{"key":"e_1_2_1_55_1","doi-asserted-by":"publisher","DOI":"10.1007\/978-3-642-81406-8_19"},{"key":"e_1_2_1_56_1","doi-asserted-by":"publisher","DOI":"10.1016\/0014-2964(76)90163-8"},{"key":"e_1_2_1_57_1","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(197810)42:4<1680::AID-CNCR2820420404>3.0.CO;2-A"},{"key":"e_1_2_1_58_1","first-page":"262","article-title":"The effect of large doses of medroxyprogesterone acetate (MPA) on urinary estrogen levels and serum levels of cortisol, T4, LH, and testosterone in patients with advanced cancer","volume":"43","author":"Sadoff L.","year":"1974","journal-title":"Obstet Gynecol"},{"key":"e_1_2_1_59_1","doi-asserted-by":"publisher","DOI":"10.1007\/BF00255272"},{"key":"e_1_2_1_60_1","unstructured":"SalimtschikM. MouridsenH. T. RoseC. Unpublished data."},{"key":"e_1_2_1_61_1","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(196710)20:10<1673::AID-CNCR2820201016>3.0.CO;2-6"},{"key":"e_1_2_1_62_1","doi-asserted-by":"crossref","first-page":"2160","DOI":"10.1016\/S0021-9258(19)42812-3","article-title":"Glucocorticoid receptors in mouse mammary tumors","volume":"249","author":"Shyamala G.","year":"1974","journal-title":"J Biol Chem"},{"key":"e_1_2_1_63_1","doi-asserted-by":"publisher","DOI":"10.1210\/jcem-21-7-753"},{"key":"e_1_2_1_64_1","doi-asserted-by":"publisher","DOI":"10.5694\/j.1326-5377.1966.tb72345.x"},{"key":"e_1_2_1_65_1","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(196710)20:10<1807::AID-CNCR2820201033>3.0.CO;2-2"},{"key":"e_1_2_1_66_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.3.5561.338"},{"key":"e_1_2_1_67_1","first-page":"600","article-title":"MPA in combination with chemotherapeutic agents for the treatment of metastatic breast cancer","volume":"3","author":"Tucker W. G.","year":"1974","journal-title":"Abstracts XI Int Cancer Congr"},{"key":"e_1_2_1_68_1","first-page":"53","article-title":"Clinical experience with antihormone therapy","author":"Ward H.","year":"1975","journal-title":"The Hormonal Control of Breast Cancer"},{"key":"e_1_2_1_69_1","doi-asserted-by":"publisher","DOI":"10.1126\/science.622569"}],"container-title":["Acta Obstetricia et Gynecologica Scandinavica"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.3109%2F00016348109157810","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/obgyn.onlinelibrary.wiley.com\/doi\/pdf\/10.3109\/00016348109157810","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,8]],"date-time":"2023-11-08T19:44:08Z","timestamp":1699472648000},"score":1,"resource":{"primary":{"URL":"https:\/\/obgyn.onlinelibrary.wiley.com\/doi\/10.3109\/00016348109157810"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[1981,1]]},"references-count":68,"journal-issue":{"issue":"S101","published-print":{"date-parts":[[1981,1]]}},"alternative-id":["10.3109\/00016348109157810"],"URL":"https:\/\/doi.org\/10.3109\/00016348109157810","archive":["Portico"],"relation":{},"ISSN":["0001-6349","1600-0412"],"issn-type":[{"value":"0001-6349","type":"print"},{"value":"1600-0412","type":"electronic"}],"subject":[],"published":{"date-parts":[[1981,1]]},"assertion":[{"value":"2011-01-11","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}